1. Metabolic Enzyme/Protease NF-κB Immunology/Inflammation
  2. HIF/HIF Prolyl-Hydroxylase Reactive Oxygen Species Endogenous Metabolite
  3. AKBA

AKBA  (Synonyms: Acetyl-11-keto-β-boswellic acid)

目录号: HY-N0892 纯度: 99.93%
COA 产品使用指南

AKBA (Acetyl-11-keto-β-boswellic acid) 是一种从乳香中提取出的活性化合物,是新颖的 Nrf2 的活化剂。

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

AKBA Chemical Structure

AKBA Chemical Structure

CAS No. : 67416-61-9

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ¥1466
In-stock
1 mg ¥594
In-stock
5 mg ¥1300
In-stock
10 mg ¥2300
In-stock
50 mg   询价  
100 mg   询价  

* Please select Quantity before adding items.

Customer Review

Other Forms of AKBA:

MCE 顾客使用本产品发表的 1 篇科研文献

查看 HIF/HIF Prolyl-Hydroxylase 亚型特异性产品:

  • 生物活性

  • 纯度 & 产品资料

生物活性

AKBA (Acetyl-11-keto-β-boswellic acid) is an active triterpenoid compound from the extract of Boswellia serrate and a novel Nrf2 activator.

细胞效力
(Cellular Effect)
Cell Line Type Value Description References
A253 cell line IC50
16.9 μM
Compound: 4, (beta-AKBA)
Cytotoxicity against human A253 cells assessed as cell survival after 96 hrs by SRB assay
Cytotoxicity against human A253 cells assessed as cell survival after 96 hrs by SRB assay
[PMID: 25618017]
A2780 IC50
14.1 μM
Compound: 4, (beta-AKBA)
Cytotoxicity against human A2780 cells assessed as cell survival after 96 hrs by SRB assay
Cytotoxicity against human A2780 cells assessed as cell survival after 96 hrs by SRB assay
[PMID: 25618017]
A549 IC50
3 μM
Compound: 4
Inhibition of microsomal PGES1 isolated from IL-1beta-stimulated human A549 cells preincubated for 15 mins followed by substrate addition measured after 1 min by RP-HPLC analysis
Inhibition of microsomal PGES1 isolated from IL-1beta-stimulated human A549 cells preincubated for 15 mins followed by substrate addition measured after 1 min by RP-HPLC analysis
[PMID: 24844534]
DLD-1 IC50
20.9 μM
Compound: 4, (beta-AKBA)
Cytotoxicity against human DLD1 cells assessed as cell survival after 96 hrs by SRB assay
Cytotoxicity against human DLD1 cells assessed as cell survival after 96 hrs by SRB assay
[PMID: 25618017]
HCT-8 IC50
17.5 μM
Compound: 4, (beta-AKBA)
Cytotoxicity against human HCT8 cells assessed as cell survival after 96 hrs by SRB assay
Cytotoxicity against human HCT8 cells assessed as cell survival after 96 hrs by SRB assay
[PMID: 25618017]
HeLa IC50
31 μM
Compound: 4, AKBA
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
[PMID: 21334793]
HL-60 IC50
11 μM
Compound: 4, AKBA
Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
[PMID: 21334793]
HT-29 IC50
19.4 μM
Compound: 4, (beta-AKBA)
Cytotoxicity against human HT-29 cells assessed as cell survival after 96 hrs by SRB assay
Cytotoxicity against human HT-29 cells assessed as cell survival after 96 hrs by SRB assay
[PMID: 25618017]
HUVEC IC50
7.45 μM
Compound: 1, AKBA
Antiproliferation activity against HUVEC cells after 48 hrs by CCK-8 assay
Antiproliferation activity against HUVEC cells after 48 hrs by CCK-8 assay
[PMID: 25819335]
LNCaP GI50
27.43 μM
Compound: AKBA
Anti-proliferative activity against human LNCAP cells measured after 96 hrs by MTT assay
Anti-proliferative activity against human LNCAP cells measured after 96 hrs by MTT assay
[PMID: 27997878]
PC-3 GI50
31.86 μM
Compound: AKBA
Anti-proliferative activity against human PC3 cells measured after 96 hrs by MTT assay
Anti-proliferative activity against human PC3 cells measured after 96 hrs by MTT assay
[PMID: 27997878]
PC-3 GI50
31.9 μM
Compound: 1; AKBA
Antiproliferative activity against human PC3 cells after 96 hrs by MTT assay
Antiproliferative activity against human PC3 cells after 96 hrs by MTT assay
[PMID: 30153964]
RAW264.7 IC50
15.6 μM
Compound: AKBA
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs
[PMID: 23391590]
Sf21 IC50
> 40 μM
Compound: 29
Inhibition of human recombinant COX2 expressed in baculovirus infected sf21 cells assessed as decrease in PGE2 formation using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition measured after 45 mins by LC-MS analysis
Inhibition of human recombinant COX2 expressed in baculovirus infected sf21 cells assessed as decrease in PGE2 formation using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition measured after 45 mins by LC-MS analysis
[PMID: 31774676]
体外研究
(In Vitro)

AKBA (Acetyl-11-keto-β-boswellic acid) 显著减少梗塞体积和凋亡细胞,并通过提高 48 小时大脑中动脉闭塞 (MCAO) 大鼠脑组织中 Nrf2 和 HO-1 的表达来增加神经系统评分再灌注后。在原代培养的神经元中,AKBA 增加了 Nrf2 和 HO-1 的表达,从而防止 OGD 诱导的氧化损伤。此外,AKBA 处理增加了 Nrf2 与抗氧化反应元件 (ARE) 的结合活性[1]
AKBA (乙酰基-11-酮基-β-乳香酸) 显著抑制人结肠腺癌的生长,表明细胞周期停滞在 G1 期并诱导细胞凋亡[3]
AKBA (乙酰基-11-酮基-β-乳香酸) 在 3T3-L1 中引发显著的脂肪分解脂肪细胞,如胞质溶胶中中性脂质减少和培养基中游离脂肪酸增加所示。AKBA 增加的脂肪分解伴随着脂肪分解酶、脂肪细胞甘油三酯脂肪酶 (ATGL) 和激素敏感性脂肪酶 (HSL) 的上调,以及脂滴稳定性调节因子 perilipin 的表达减少。此外,AKBA (Acetyl-11-keto-β-boswellic acid) 处理减少了成熟脂肪细胞中成熟脂肪细胞 aP2、脂联素和 glut-4 的表型标记[5]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

AKBA (Acetyl-11-keto-β-boswellic acid) 显著阻止了肠腺瘤性息肉的形成,对小鼠没有毒性。AKBA 在预防小肠和结肠息肉方面的活性比阿司匹林更有效。组织病理学检查显示 AKBA 的作用,即减少息肉大小和异型增生程度,在较大尺寸的息肉中更为突出,尤其是那些起源于结肠的息肉[1]
AKBA 在小鼠中给药有效地延迟了 HT-29 异种移植物的生长而没有毒性迹象。AKBA 的活性比阿司匹林强[3]
AKBA 在体外和体内均表现出抗癌活性。通过在小鼠中口服应用,AKBA 可显著抑制 SGC-7901 和 MKN-45 异种移植物,且无毒性[4]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

512.72

Formula

C32H48O5

CAS 号
性状

固体

颜色

White to off-white

中文名称

3-乙酰基-11-酮基-β-乳香酸

结构分类
初始来源
运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
溶解性数据
细胞实验: 

DMSO 中的溶解度 : ≥ 5.2 mg/mL (10.14 mM; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

* "≥" means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.9504 mL 9.7519 mL 19.5038 mL
5 mM 0.3901 mL 1.9504 mL 3.9008 mL
查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 2 years; -20°C, 1 year。-80°C储存时,请在2年内使用, -20°C储存时,请在1年内使用。

  • 摩尔计算器

  • 稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量
=
浓度
×
体积
×
分子量 *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start)

C1

×
体积 (start)

V1

=
浓度 (final)

C2

×
体积 (final)

V2

动物溶解方案计算器
请输入动物实验的基本信息:

给药剂量

mg/kg

动物的平均体重

g

每只动物的给药体积

μL

动物数量

由于实验过程有损耗,建议您多配一只动物的量
计算结果
工作液所需浓度 : mg/mL
纯度 & 产品资料

纯度: 99.93%

完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 2 years; -20°C, 1 year。-80°C储存时,请在2年内使用, -20°C储存时,请在1年内使用。

可选溶剂 浓度 溶剂体积 质量 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 1.9504 mL 9.7519 mL 19.5038 mL 48.7596 mL
5 mM 0.3901 mL 1.9504 mL 3.9008 mL 9.7519 mL
10 mM 0.1950 mL 0.9752 mL 1.9504 mL 4.8760 mL
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称:

 

* 需求量:

* 客户姓名:

 

* Email:

* 电话:

 

* 公司或机构名称:

   留言给我们:

Bulk Inquiry

Inquiry Information

产品名称:
AKBA
目录号:
HY-N0892
需求量: